Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ironest is an oral hematinic combination product developed and marketed by Prisure Medicare. It is primarily indicated for the treatment and prevention of iron deficiency anemia, particularly in gynecological contexts such as pregnancy and lactation. The formulation typically consists of ferrous ascorbate and folic acid. Ferrous ascorbate is a synthetic chelate of ferrous iron and ascorbic acid (Vitamin C) that offers high elemental iron content with superior bioavailability and lower gastrointestinal side effects compared to traditional iron salts. Folic acid (Vitamin B9) is included to support erythropoiesis, facilitate DNA synthesis, and prevent neural tube defects in the developing fetus.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Ironest.